01 Integrated Perfusion Monitoring Enhances Vascular CareThe skin perfusion pressure (SPP) testing devices market is driven by the move toward integrated diagnostic platforms that combine key vascular parameters, such as compartment pressure (CP), diastolic blood pressure (DBP), and perfusion pressure (ΔP), into a single, portable system. With rising demand for non-invasive, real-time diagnostic tools, especially in trauma care, diabetic foot ulcer (DFU) management, and critical limb ischemia (CLI) assessment, manufacturers are introducing multifunctional devices that eliminate the need for separate instruments while enhancing diagnostic precision and patient outcomes.For example, in March 2025, MY01 received FDA clearance for its next-generation perfusion monitoring feature, which integrates CP, DBP, and ΔP readings into a single device.The integration of multi-parameter functionality is a driving force in reshaping vascular assessment practices and broadening access to critical diagnostic information in both hospital and community-based care environments.
01 Telehealth Expansion and Ai IntegrationA significant driver of the skin perfusion pressure testing devices market in 2025 is the healthcare sector’s shift toward AI-enabled diagnostics and remote monitoring, which is driving demand for portable, connected SPP devices across outpatient and decentralised care settings. With the rising burden of diabetes-related vascular complications and chronic wounds, point-of-care solutions for early perfusion assessment are becoming central to preventative care models.The growth of telehealth infrastructure and clinical demand for fast, quantitative diagnostics is encouraging providers to deploy compact SPP devices in non-traditional settings. Manufacturers developing AI-enhanced, cloud-connected models are well-positioned to capture rising market interest.
01 Lack of Standardised Diagnostic Protocols Limits Clinical IntegrationThe absence of universally accepted clinical guidelines and diagnostic thresholds for interpreting SPP results restricts the market. Unlike more established diagnostics such as the ankle-brachial index (ABI), SPP testing lacks global consensus on cutoff values for ischemia or perfusion adequacy. For instance, some vascular clinics interpret an SPP of <30 mmHg as critical ischemia, while others use different benchmarks depending on patient comorbidities, wound depth, or device calibration. This variability can lead to discrepancies in diagnosis, delayed interventions, or redundant testing with other modalities.Furthermore, the diversity of device technologies, ranging from laser Doppler systems to photoplethysmography-based tools, may yield different readings under the same clinical conditions. The absence of calibration standards and cross-platform validation hampers clinical confidence and slows device adoption, particularly in hospitals prioritising evidence-based practice.
01 Advanced Vascular Imaging Technique Unlocks Enhanced Diagnostic AccuracyA promising breakthrough emerged with developing a novel imaging technique that combines Laser Speckle Contrast Imaging (LSCI) with advanced data processing methods, specifically principal component analysis and entropy filtering. This approach significantly enhances image contrast, minimises interference from static tissue scatterers, and improves sensitivity to subtle changes in blood flow velocity. These advancements are critical in non-invasive vascular assessment, enabling clinicians to detect and monitor vascular abnormalities with greater accuracy and efficiency.Beyond improving diagnostic accuracy, this technology opens new avenues for clinical applications across chronic wound care, diabetes management, and other conditions where the microcirculatory function is key.
December 2025 Vascular diagnostic technology providers continued advancing non-invasive perfusion assessment solutions, including laser Doppler-based and photoplethysmography-based technologies used for evaluating tissue blood flow and wound-healing potential. Companies active in this space include Moor Instruments Limited, Perimed AB, Viasonix, and Koven Technology, which develop vascular measurement systems supporting peripheral vascular assessment and wound care applications.
September 2025 Medical device developers continued improving portable and bedside vascular assessment technologies designed for easier clinical use in hospitals, wound-care centers, and ambulatory settings. Advancements focused on improving measurement accuracy, device portability, and integration of perfusion monitoring into vascular diagnostics workflows.
July 2025 Companies working on optical vascular measurement technologies continued developing laser Doppler and photoplethysmography-based systems that support evaluation of microcirculation and tissue perfusion. These technologies are increasingly used alongside traditional vascular diagnostic approaches for wound management and peripheral artery disease assessment.
May 2025 Perimed AB and other vascular diagnostic technology providers continued supporting research and clinical applications involving microcirculation measurement technologies. Their solutions include laser Doppler systems used for assessing blood perfusion changes in clinical research and vascular applications.